The company has achieved even higher specificity than earlier data demonstrated, and is now building up its sales and marketing infrastructure for the planned launch of its lung cancer test.
The firm's Cxbladder Monitor test was shown to have a high negative predictive value compared to other commercially available urine diagnostic tests for bladder cancer.
The company plans to outlicense the assay, developed using a custom Affymetrix microarray, to an interested partner.
The company is moving forward in working with early adopters in a limited setting of lung cancer testing, but still plans to expand its test to other cancers soon.
The partnership is part of a broader agreement between Genome BC and Genomics England to share data and tools around cancer and rare and infectious diseases.
The researchers designed a synthetic DNA method to be used as internal controls for NGS assays that could be applied to oncology, metagenomics, and immunology.
The European Molecular Genetics Quality Network, a provider of proficiency testing services for clinical genetics and molecular pathology labs, and its UK partner have been developing a new assessment scheme for NGS labs.
The company presented its findings last week at the 2016 Gastrointestinal Cancer Symposium and is preparing to launch the assay in the US later this year.
Novacyt will validate its Novaprep liquid-based cytology platform with Abbott's RealTime High Risk human papillomavirus assay.
The partially reinstated US travel ban leaves space for uncertainty for researchers, Nature News says.
Researchers find a number of traits differ by sex and could affect mouse model studies, according to Reuters.
Tweaking the skin microbiome could help address some skin conditions, the New York Times reports.
In PNAS this week: DNA methylation profiles of tumor tissue, gene dynamics in prokaryotes, and more.